Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus HALCION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus HALCION.
DORAL vs HALCION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
15-30 mg orally at bedtime, maximum 60 mg/day.
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Category C
Category C
Benzodiazepine
Benzodiazepine